Similar differences were observed with interleukin 22 ( IL22 ) mRNA showing early downregulation for adalimumab responders ( week 2 , -3.17 [ 1.00 ] , P < .001 ; week 16 , -3.58 [ 1.00 ] , P < .001 ) compared with late downregulation for methotrexate responders ( week 2 , -0.44 [ 0.68 ] , P = .64 ; week 16 , -5.14 [ 0.68 ] , P < .001 ) .